Loading
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Regular session
$1.002
−$0.018 · -1.76%
Regular session · ET · Market data may be delayed.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Day range
Current $1.002
52-week range
Current $1.002
Regular session · ET · Market data may be delayed.
GoAI Score
Strong sell
Valuation
20
Overpriced
Sentiment
41
Mixed
Risk
98
Extreme Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Day range
Current $1.002
52-week range
Current $1.002
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 500K USD | — | 28.83M USD | −483K USD |
| Cost of goods sold | 460K USD | — | 1.42M USD | 1.86M USD | — |
| Gross profit | −460K USD | 500K USD | −1.42M USD | 26.97M USD | −483K USD |
| Research and development | 3.29M USD | — | 1.42M USD | 19.77M USD | 48.98M USD |
| Selling, general, and administrative | 6.83M USD | 5.45M USD | 12.65M USD | 10.89M USD | 13.09M USD |
| Operating expenses | 9.66M USD | 12.73M USD | 13.57M USD | 28.8M USD | 62.07M USD |
| Interest income | 29K USD | 8K USD | 32K USD | 15K USD | 141K USD |
| Interest expense | 1K USD | 18K USD | — | 595K USD | 1.69M USD |
| Depreciation and amortization | 460K USD | 824K USD | 1.38M USD | 1.86M USD | 1.78M USD |
| Operating income | −10.12M USD | −12.23M USD | −15M USD | −1.83M USD | −62.55M USD |
| Net income | −4.95M USD | −9.7M USD | −16.91M USD | −2.58M USD | −64.1M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
1097.60% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 28, 2024 | 1:5 | — | — |
Stock split | Jun 30, 2022 | 1:30 | — | — |
Effective Aug 28, 2024
1:5
Effective Jun 30, 2022
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
